Fayetteville, ARNCT06115603Now EnrollingIRB Ready

Attention-Deficit/Hyperactivity Disorder Clinical Trial in Fayetteville, AR

Access cutting-edge attention-deficit/hyperactivity disorder treatment through this clinical trial at a research site in Fayetteville. Study-provided care at no cost to qualified participants.

Sponsored by University of Arkansas, Fayetteville

Quick Self-Assessment

See if you qualify for this Fayetteville location

Preparing your pre-screening questions…

Expert Care in Fayetteville

Access attention-deficit/hyperactivity disorder specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related attention-deficit/hyperactivity disorder treatment provided free

Apply for This Fayetteville Location

Check if you qualify for this attention-deficit/hyperactivity disorder clinical trial in Fayetteville, AR

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Fayetteville

    Convenient for AR residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Fayetteville site if eligible
  4. 4Begin participation

About This Attention-Deficit/Hyperactivity Disorder Study in Fayetteville

The goal of this clinical trial is to evaluate the effects of Cannabigerol (CBG) on indicators of Attention-Deficit/Hyperactivity Disorder (ADHD) in a sample of participants indicating/reporting symptoms associated with ADHD. The main question it aims to answer is: Does CBG reduce ADHD-related indicators relative to placebo? Participants will administer an acute dose of placebo or 80mg CBG and complete outcome measures at 45 minutes and 75 minutes. Daily surveys to monitor safety will be administered for one week following administration.

Sponsor: University of Arkansas, Fayetteville

Who Can Participate

Inclusion Criteria

Between 18 and 55-years-old.
BMI between 18 and 35 kg/m2.
Score a 4 or above on the Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist Part A.
Meet diagnostic criteria for ADHD with a current severity rating of at least mild as defined by the DIAMOND.
Are not pregnant or currently breastfeeding.
Have no history of significant allergic condition, hypersensitivity, or allergic reactions to cannabis, cannabinoid medications, hemp products, medium chain triglyceride oil, or peppermint.
Have not used CBG or any other cannabinoid products in the past 30 days.
Willing to abstain from using cannabis or any THC-containing product for the duration of the study.
Have never used a synthetic cannabinoid or cannabinoid analogue (e.g., dronabinol, nabilone), or a synthetic cannabinoid receptor agonist (e.g., spice, k2).
Have not been exposed to any investigational drug or device 30 days prior to screening and you have no plans to take an investigational drug during the study.
Willing to maintain a stable treatment regimen (i.e., no change in current medication use) for the duration of the study.
Not currently taking a prescription medication for ADHD and have not been prescribed a medication for ADHD in the past six months.
Not currently having thoughts of committing suicide
Does not meet criteria for current severe major depressive disorder or a substance use disorder.
Have not been diagnosed with bipolar disorder or psychosis.
Do not have an acute illness, such as a respiratory infection or other illness that would interfere with study participation; not currently taking medication for an acute illness (e.g., antibiotic).
Do not have history of diagnosis related to liver function and/or significantly impaired liver function (e.g., cirrhosis of the liver, hepatitis).
Willing to ensure they have used effective contraception (for example, oral contraception, double barrier, intra-uterine device) for 30 prior to the study and for 30 days after study completion.
Have access to a ride to the University of Arkansas campus for research appointments.
Willing to comply with current university mandates as they pertain to COVID-19 protocols (e.g., mask wearing).
Do not have any serious or unstable physical health conditions including neurological or renal illness.
Do not have any current or historical cardiovascular conditions, including hypotension, bradycardia, or heart block.
No atrial fibrillation, bradycardia, or tachycardia detected via mobile electrocardiogram during the in-laboratory visit.
No recent illicit drug use other than cannabis, or alcohol use in the 12 hours preceding the in-laboratory visit.
Not currently prescribed or taking the following medications:
Valproic acid
Phenobarbital
Mechanistic Target of Rapamycin \[mTOR\] Inhibitors
Oral tacrolimus
St. John's wort
Escitalopram
Cardiovascular medications
Strong CYP3A4 inhibitors (e.g., ketoconazole)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Fayetteville?

Yes, this clinical trial (NCT06115603) has an active research site in Fayetteville, AR that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Attention-Deficit/Hyperactivity Disorder Treatment Options in Fayetteville, AR

If you're searching for attention-deficit/hyperactivity disorder treatment options in Fayetteville, AR, this clinical trial (NCT06115603) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Fayetteville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced attention-deficit/hyperactivity disorder specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all attention-deficit/hyperactivity disorder clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in Fayetteville, AR

See all pulmonary embolism clinical trials recruiting in Fayetteville — not just this study.

Browse Pulmonary Embolism Trials in Fayetteville →

Browse More Trials by Condition

Pulmonary Embolism TrialsADHD TrialsRheumatoid Arthritis TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Fayetteville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Fayetteville, AR